Medical Device News Posts

MicroPort Orthopedics Complete Profemur Gladiator Hip System Now Available

More articles

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

MicroPort Orthopedics announced the availability of its Profemur® Gladiator® HA Collared Stem and Profemur® Gladiator® Cemented Collared Stem.

Combined with its current Profemur® Gladiator® Plasma Stem, the Gladiator® Hip Stem System is now complete, offering  a wide range of indications in the treatment of both high demand total hip arthroplasties and low demand fracture patients.
Designed for primary hip replacement surgery, the Profemur® Gladiator® Hip Stems all offer a triple wedge tapered design with distinct geometry. The hip stem is designed with a reduced lateral shoulder convenient for tissue-sparing techniques, making it perfectly suited to be used with MicroPort’s disruptive innovation through the Anterior Path® surgical approach.  The Profemur® line of Hip Stems gives surgeons the versatility to address their patients’ needs with one set of instruments in this truly comprehensive system.
“By allowing surgeons to cater a femoral hip system to their preferred techniques, we have created a customizable hip system that is Simply Versatile™ in its ability to exceed the needs of each surgeon, designed to help our surgeons more effectively treat patients,” said Benny Hagag, President of MicroPort Orthopedics. “This customization to tissue-sparing techniques allows for streamlined preoperative planning, excellent patient outcomes1,2, and a quicker recovery3. The proof is in our patients.”
- Advertisement -spot_img

Latest